Absci Corp ABSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
-
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
-
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
-
Absci to Participate in Upcoming Investor Conferences
-
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
-
Healthcare stocks have become a haven for investors ditching tech
-
Absci Reports Data From Trial for Hair-Loss Treatment, Prices $100 Million Stock Offering
-
Absci Shares Fall on Wider 4Q Loss, Lower Revenue
Trading Information
- Previous Close Price
- $10.04
- Day Range
- $8.93–9.95
- 52-Week Range
- $2.24–12.06
- Bid/Ask
- $9.38 / $9.70
- Shares Outstanding
- 171.61M
- Market Cap
- $1.61B
- Volume/Avg
- 1,754 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 908.56
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 140
- Website
- https://www.absci.com
Valuation
|
Metric
|
ABSI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.53 |
Price/Sales | 908.56 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ABSI
|
|---|---|
Quick Ratio | 10.26 |
Current Ratio | 10.63 |
Interest Coverage | −1,287.05 |
Quick Ratio
ABSI
Profitability
|
Metric
|
ABSI
|
|---|---|
Return on Assets (Normalized) | −47.51% |
Return on Equity (Normalized) | −54.43% |
Return on Invested Capital (Normalized) | −52.93% |
Return on Assets
ABSI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|x#$?&$ | LOCK|$>nq& | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|LB!R!m% | LOCK|RtlWC | $84B | |||
| Moderna Inc
MRNA
| LOCK|jr!$%W# | LOCK|JmY | $81B | |||
| argenx SE ADR
ARGX
| LOCK|wN!swy | LOCK|<P< | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#>>%<Hd | LOCK|DGV | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|w?S??? | LOCK|csbY | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#@!#Y%! | LOCK|&<!Y> | $28B | |||
| Incyte Corp
INCY
| LOCK|#vlvV?M | LOCK|?C | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|BdS?@<< | LOCK|f?P | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&<b&S>Y | LOCK|@rp | $14B |
United States